β-Galactoside prodrugs of doxorubicin for application in antibody directed enzyme prodrug therapy/prodrug monotherapy

Archives of Pharmacal Research

Volumn 30, Issue 6, 2007, Pages 723-732

  Devalapally, HariKrishna ^a,c   Navath, Raghavendra Swamy ^b   Yenamandra, Venkateshwarlu ^b   Akkinepally, RaghuRam Rao ^a   Devarakonda, Rama Krishna ^a  

^a KAKATIYA UNIVERSITY   (India)

^b INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^c NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Doxorubicin; Hydrolysis; In vitro cytotoxicity; Prodrugs; Release kinetics; Stability

Indexed keywords

EID: 34347376957     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02977634     Document Type: Article

References (24)

1. Arcamone, F., Doxorubicin antibiotics: Medicinal Chemistry, A Series of Mono-graphs. G. De Stevens (Ed.). Academic Press, New York, pp. 17 (1982).
2. Azoulay, M., Florent, J. -C., Monneret, C., Gesson, J. P., Jacquesy, J. C., Tillequin, F., Koch, M., Bosslet, K., Czech, J., and Hoffman, D., Prodrugs of anthracycline antibiotics suited for tumor-specific activation. Anti Cancer Drug Des., 10, 441-450 (1995).
3. Bagshawe, K. D., Antibody directed enzymes revive anti-cancer prodrugs concept. Br. J. Cancer., 56, 531-532 (1987).
4. Bagshawe, K. D., Springer, C. J., Searle, F., Antoniw, P., Sharma, S. K., Melton, R. G., and Sherwood, R. F., A cytotoxic agent can be generated selectively at cancer site. Br. J. Cancer, 58, 700-703 (1988).
5. Bagshawe, K. D., Sharma, S. K., Springer, C. J., Antoniw, P., Boden, J. A., Rogers, G.T., Burke, P. J., Melton, R. G., and Sherwood, R. F., Antibody directed enzyme prodrug therapy (ADEPT): clinical report. Dis. Markers, 9, 233-238 (1991).
6. Bagshawe, K. D., Antibody-directed enzyme prodrug therapy. Clin. Pharmacokinet., 27, 368-376 (1994).
7. Bollenback, G. N., Long, J. W., Benjamin, D. G., and Lindquist, J. A., The Synthesis of Aryl-D-glucopyranosiduronic Acids. J. Am. Chem. Soc., 77, 3310-3315 (1955).
8. Bosslet, K., Czech, J., and Hoffmann, D., A novel one-step tumor-selective prodrug activation system. Tumor Targeting., 1, 45-50 (1995).
9. Bosmann, H. B. and Hall, T. C., Enzyme activity in invasive tumors of human breast and colon. Proc. Natl. Acad. Sci. U. S. A., 71, 1833-1837 (1974).
10. Carl, P. L., Chakravarthy, P. K., and Katzenellenbogen, J. A., A novel linkage applicable in prodrug design. J. Med. Chem., 24, 479-480 (1981).
11. Chabner B. A., Allegra C. J., Curt G. A., and Calabresi P., In Hardman, J. G., Limbird, L.E., Molinoff, P. B., Ruddon, R. W., Gilman, L. S., and Goodman A. (Eds.). Goodman and Gilman's The Pharmacological basis of therapeutics; McGraw-Hill, New-York, pp. 1233-1257 (1996).
12. Connors, T. A., Antibody-directed enzyme prodrug therapy. Cancer Cells, 2, 56-57 (1990).
13. Florent, J. -C., Dong, X., Gaudel, G., Mitaku, S., Monneret, C., Gesson, J. -P., Jacquesy, J. -C., Mondon, M., Renoux, B., Andrianomenjanahary, S., Michel, S., Koch, M., Tillequin, F., Gerken, M., Czech, J., Straub, R., and Bosslet, K., Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy. J. Med. Chem., 41, 3572-3581 (1998).
14. Gerken, M., Krause, M., and Czech, J., Anthracycline-glycosyl prodrugs. Verfahren zu ihrer Herstellung und ihre Verwendung in Kombination mit functionalisierten tumorspezifischen Enzymconjugaten. European Patent 91101096.5, (1991) 28.01.91.
15. Gesson, J. -P., Jacquesy, J. -C., Mondon, M., Petit, P., Renoux, B., Andrianomenjanahary, S., Dufat-Trinh Van, H., Koch, M., Michel, S., Tillequin, F., Florent, J. -C., Monneret, C., Bosslet, K., Czech, J. and Hoffmann D., Prodrugs of anthracyclines for chemotherapy via enzyme-monoclonal antibody conjugates. Anticancer Drug Des., 9, 409-423 (1994).
16. Ghosh, A. K., Khan, S., Frank Marini, J., and Nelson J. A., A daunorubicin β-galactoside prodrug for use in conjunction with gene-directed enzyme prodrug therapy. Tetrahedron Lett., 41, 4871-4874 (2000).
17. HariKrishna, D., Rao, A. R., and Krishna, D. R., Selective activation of anthracycline prodrugs for use in conjunction with ADEPT. Drugs News and Perspect., 16, 309-318 (2003).
18. Krishna, D. R., Sperker, B., Fritz, P., and Klotz, U., Does pH 6 beta-galactosidase activity indicate cell senescence?. Mech. Ageing Dev., 109, 113-123 (1999).
19. Michael, J. B. and Tannock, I. F., Lysosomes, lysosomal enzymes and cancer. Adv. Cancer Res., 60, 269-291 (1993).
20. Rivalt, F., Tranoy-opalenski, I., and Gesson, J. -P., A new linker for glucuronylated anticancer prodrugs. Bioorg. Med. Chem., 12, 675-682 (2004).
21. Senter, P. D., Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy. FASEB J., 4, 188-193 (1990).
22. Senter, P. D. and Springer, C. J., Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv. Drug Deliv. Rev., 53, 247-284 (2001).
23. Skehan, P., Storeng, R., Scudiero, D., Moks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenny, S., and Boyd, M. R., New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82, 1107-1112 (1990).
24. Yuan, F., Baxter, L., and Jai, R. K., Pharmacokinetic analysis or two-step approaches using bifunctional and enzyme conjugated antibodies. Cancer Res., 51, 3119-3130 (1991).